BMS Completes Acquisition of Inhibitex

Bristol-Myers Squibb has announced the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc.

Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. at a purchase price of $26.00 per share.

As of the expiration of the offer, 77,532,611 shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer. As of the close of business on February 10, 2012, approximately 4,260,705 shares remained subject to guaranteed delivery procedures.

Today, BristolMyers Squibb acquired all of the remaining outstanding shares of Inhibitex common stock by means of a "short form merger" in which all such shares were converted into the right to receive $26.00 per share, in cash and without interest